Hemangioma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Diagnosis, By Treatment, By End user, By Region & Competition, 2021-2031F

Description

The Global Hemangioma Treatment Market is projected to expand from USD 326.43 Million in 2025 to USD 431.48 Million by 2031, registering a CAGR of 4.76%. This market includes both surgical and pharmacological interventions aimed at treating infantile hemangiomas, which are benign vascular tumors marked by rapid endothelial growth. Growth is largely fueled by a growing focus on early detection and a clinical preference for proactive measures to avoid permanent disfigurement or functional issues. Data from the Vascular Birthmarks Foundation in 2024 indicates that roughly 10% of infants with vascular birthmarks require specialized medical attention, underscoring the significant need for effective therapeutic solutions and driving the ongoing refinement of laser therapies and beta-blockers for pediatric use.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 326.43 Million
Market Size 2031	USD 431.48 Million
CAGR 2026-2031	4.76%
Fastest Growing Segment	Laser Therapy
Largest Market	North America

Despite these drivers, the market encounters a major obstacle related to the safety of primary drug therapies. The risk of systemic side effects from oral propranolol, such as bradycardia and hypoglycemia, necessitates strict monitoring protocols that can hinder treatment compliance and discourage prescribing in non-specialized settings. Consequently, these safety concerns lead many healthcare providers to favor conservative management for milder cases, thereby restricting the wider implementation of active medical treatments.

Market Driver

The therapeutic framework for infantile hemangiomas is anchored by the widespread use of beta-blockers as the primary standard of care. Oral propranolol is particularly favored for managing proliferating and high-risk tumors because of its capacity to accelerate regression and prevent lasting physical damage. This dominance is supported by recent efficacy data; a December 2024 article in Frontiers in Pharmacology titled "Efficacy and safety of oral propranolol and topical timolol in the treatment of infantile hemangioma" noted that oral propranolol achieved a superior response rate with an odds ratio of 2.12 compared to topical treatments. This data ensures systemic beta-blockers remain the go-to option for physicians treating complex vascular anomalies that pose risks to vital functions or aesthetics.

Simultaneously, there is a noticeable trend toward minimally invasive and non-invasive therapies intended to reduce the systemic risks linked to oral medications. For superficial and uncomplicated lesions, clinicians are increasingly utilizing topical beta-blockers to balance therapeutic effectiveness with patient safety. According to a September 2025 Medscape article, "Infantile Hemangioma Visits and Topical Treatments Increase in the US," prescriptions for topical timolol accounted for 18.60% of hemangioma-related visits, significantly surpassing the 10.28% for systemic propranolol. The persistent need for expert care across all severity levels is further evidenced by the Vascular Birthmarks Foundation, which provided 589 free clinic services worldwide in 2024.

Market Challenge

The central impediment to the Global Hemangioma Treatment Market is the safety profile associated with first-line pharmacological treatments, particularly the systemic risks of oral beta-blockers. While oral propranolol serves as the standard of care, its potential to cause adverse events like hypotension, bradycardia, and hypoglycemia creates a substantial barrier to broad usage. These risks require intensive patient monitoring, often involving extended observation or inpatient admission during the initial phase of treatment. Such demands impose logistical challenges and liability issues for general practitioners, resulting in a hesitation to administer these therapies outside of specialized facilities.

This caution fosters a preference for observation or "active non-intervention" in patients with uncomplicated lesions, effectively reducing the market for pharmaceutical therapies. Physicians often balance the clinical advantages against the risk of systemic toxicity, frequently choosing to forgo medication in mild-to-moderate cases. Data from the Pediatric Dermatology Research Alliance in 2025 highlights this trend, showing that observation was the leading management strategy for low-risk infantile hemangiomas, chosen in roughly 56% of instances over active therapy. This conservative approach directly constrains market volume by diverting a large portion of the diagnosable population away from revenue-generating treatments due to safety concerns.

Market Trends

The landscape of vascular anomaly management is being transformed by the integration of advanced dual-wavelength laser systems, which overcome the constraints of single-wavelength devices. Providers are increasingly utilizing platforms that combine Nd:YAG and Pulsed Dye Laser (PDL) technologies to simultaneously treat deep and superficial hemangioma components, improving clearance rates and decreasing the number of necessary sessions. This technology enables deeper tissue penetration while protecting the epidermis, proving especially useful for mixed-type or resistant lesions that respond poorly to standard drugs. For example, Candela Medical Inc. launched the Vbeam Pro laser platform in April 2025, featuring both 1064 nm Nd:YAG and 595 nm pulsed dye laser wavelengths to enhance safety and efficacy for pediatric patients.

In parallel, there is a significant shift toward specialty clinics and outpatient settings, driven by the necessity for multidisciplinary, expert care outside of general hospitals. Because hemangioma cases demand accurate therapeutic and diagnostic differentiation, patient care is consolidating in centers of excellence capable of providing everything from laser interventions to diagnostic imaging. This model ensures timely and correct treatment for infants, reducing risks linked to delayed or improper management in general settings. Underscoring the demand for such specialized expertise, the Vascular Birthmarks Foundation reported facilitating 309 diagnostic consultations via its global clinic network in 2024, highlighting the vital role of targeted outpatient services in enhancing patient results.

Key Market Players

Cutera Inc
Merck & Co., Inc.
AbbVie Inc
Akorn Operating Company LLC
Pfizer Inc
Alma Lasers Ltd
Linline Medical Systems Ltd.
Pierre Fabre SA
IRIDEX Corporation

Report Scope

In this report, the Global Hemangioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemangioma Treatment Market, By Type

Capillary Hemangioma
Cavernous Hemangioma
Compound Hemangioma
Lobular Capillary Hemangioma

Hemangioma Treatment Market, By Diagnosis

Ultrasound
MRI
CT Scan
Others

Hemangioma Treatment Market, By Treatment

Medical Therapy
Laser Therapy
Surgery
Beta Blocker Medicines
Others

Hemangioma Treatment Market, By End user

Hospitals & Clinics
Diagnostic Centers
Others

Hemangioma Treatment Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemangioma Treatment Market.

Available Customizations:

Global Hemangioma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hemangioma Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Capillary Hemangioma, Cavernous Hemangioma, Compound Hemangioma, Lobular Capillary Hemangioma)
- 5.2.2. By Diagnosis (Ultrasound, MRI, CT Scan, Others)
- 5.2.3. By Treatment (Medical Therapy, Laser Therapy, Surgery, Beta Blocker Medicines, Others)
- 5.2.4. By End user (Hospitals & Clinics, Diagnostic Centers, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Hemangioma Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Diagnosis
- 6.2.3. By Treatment
- 6.2.4. By End user
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Hemangioma Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Diagnosis
    - 6.3.1.2.3. By Treatment
    - 6.3.1.2.4. By End user
- 6.3.2. Canada Hemangioma Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Diagnosis
    - 6.3.2.2.3. By Treatment
    - 6.3.2.2.4. By End user
- 6.3.3. Mexico Hemangioma Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Diagnosis
    - 6.3.3.2.3. By Treatment
    - 6.3.3.2.4. By End user

7. Europe Hemangioma Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Diagnosis
- 7.2.3. By Treatment
- 7.2.4. By End user
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Hemangioma Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Diagnosis
    - 7.3.1.2.3. By Treatment
    - 7.3.1.2.4. By End user
- 7.3.2. France Hemangioma Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Diagnosis
    - 7.3.2.2.3. By Treatment
    - 7.3.2.2.4. By End user
- 7.3.3. United Kingdom Hemangioma Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Diagnosis
    - 7.3.3.2.3. By Treatment
    - 7.3.3.2.4. By End user
- 7.3.4. Italy Hemangioma Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Diagnosis
    - 7.3.4.2.3. By Treatment
    - 7.3.4.2.4. By End user
- 7.3.5. Spain Hemangioma Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Diagnosis
    - 7.3.5.2.3. By Treatment
    - 7.3.5.2.4. By End user

8. Asia Pacific Hemangioma Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Diagnosis
- 8.2.3. By Treatment
- 8.2.4. By End user
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Hemangioma Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Diagnosis
    - 8.3.1.2.3. By Treatment
    - 8.3.1.2.4. By End user
- 8.3.2. India Hemangioma Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Diagnosis
    - 8.3.2.2.3. By Treatment
    - 8.3.2.2.4. By End user
- 8.3.3. Japan Hemangioma Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Diagnosis
    - 8.3.3.2.3. By Treatment
    - 8.3.3.2.4. By End user
- 8.3.4. South Korea Hemangioma Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Diagnosis
    - 8.3.4.2.3. By Treatment
    - 8.3.4.2.4. By End user
- 8.3.5. Australia Hemangioma Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Diagnosis
    - 8.3.5.2.3. By Treatment
    - 8.3.5.2.4. By End user

9. Middle East & Africa Hemangioma Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Diagnosis
- 9.2.3. By Treatment
- 9.2.4. By End user
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Hemangioma Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Diagnosis
    - 9.3.1.2.3. By Treatment
    - 9.3.1.2.4. By End user
- 9.3.2. UAE Hemangioma Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Diagnosis
    - 9.3.2.2.3. By Treatment
    - 9.3.2.2.4. By End user
- 9.3.3. South Africa Hemangioma Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Diagnosis
    - 9.3.3.2.3. By Treatment
    - 9.3.3.2.4. By End user

10. South America Hemangioma Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Diagnosis
- 10.2.3. By Treatment
- 10.2.4. By End user
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Hemangioma Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Diagnosis
    - 10.3.1.2.3. By Treatment
    - 10.3.1.2.4. By End user
- 10.3.2. Colombia Hemangioma Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Diagnosis
    - 10.3.2.2.3. By Treatment
    - 10.3.2.2.4. By End user
- 10.3.3. Argentina Hemangioma Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Diagnosis
    - 10.3.3.2.3. By Treatment
    - 10.3.3.2.4. By End user

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Hemangioma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Cutera Inc
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Merck & Co., Inc.
15.3. AbbVie Inc
15.4. Akorn Operating Company LLC
15.5. Pfizer Inc
15.6. Alma Lasers Ltd
15.7. Linline Medical Systems Ltd.
15.8. Pierre Fabre SA
15.9. IRIDEX Corporation